Canton Strategic Holdings (CNTN) Non-Current Assets (2025 - 2026)
Canton Strategic Holdings (CNTN) reported Non-Current Assets of $541.6 million for Q1 2026, up 7.93% quarter-over-quarter from $501.8 million in Q4 2025.
Canton Strategic Holdings (CNTN) Non-Current Assets (2025 - 2026) Analysis & Trends
Canton Strategic Holdings has reported Non-Current Assets for 2 years, with the latest figure at $541.6 million in Q1 2026.
- For the quarter ending Q1 2026, Non-Current Assets changed N/A year-over-year to $541.6 million; the trailing twelve-month figure through Mar 2026 stood at $1.0 billion (changed N/A YoY), and the FY2025 full-year result was $501.8 million, changed N/A from the prior year.
- Non-Current Assets for Q1 2026 stood at $541.6 million, up from $501.8 million in the prior quarter.
- The five-year high for Non-Current Assets was $541.6 million in Q1 2026, with the low at $501.8 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 62,953.78 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 289.41 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 4.56 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 486.60 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 30.30 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 5.18 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 14.75 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 39.71 Mn |
| 10 | Canton Strategic Holdings | 699.97 Mn | 658.44 Mn | - | 541.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 541.57 Mn |
| Dec 31, 2025 | 501.76 Mn |